Biotech | January 18, 2022
DCGI approves Phase 3 clinical trial of Stempeucel to treat Covid-19 patients
The drug is aimed at treating Covid-19 patients with Acute Respiratory Distress Syndrome (ARDS)
The drug is aimed at treating Covid-19 patients with Acute Respiratory Distress Syndrome (ARDS)
The global multi-center phase-II clinical trial will be a 36-week, multi-center, randomized, double-blind, placebo-controlled trial, followed by a 36-week open-label extension period
It is the first monoclonal antibody drug for use in any animal species
The new plant at Slovenská ?up?a site in Slovakia is scheduled to come on stream in two years
In-house wet testing with live Omicron virus demonstrated that the Antigen test detects the Omicron variant with comparable sensitivity to other variants
The last date to apply for this program is 18th January 2022
Danny Bar-Zohar will become Global Head of R&D and Joern-Peter Halle will become Chief Strategy Officer
Under the terms of the agreement, Arrakis will lead research activities for the identification of RNA-targeted small molecule (rSM) binders against a broad set of targets nominated by Amgen
This surpasses the number of approvals supported in 2020
Ind-Ra expects revenue growth of over 12% in 2022.
Subscribe To Our Newsletter & Stay Updated
